Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 5,782 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Disease Clear all
Completed Phase 2 Interventional Results available

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

NCT03041311
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Trilaciclib, Placebo, Carboplatin, Etoposide, Atezolizumab
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Beverly Hills, California • Fullerton, California • Loma Linda, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Informed Consent Formats by Information Preference and Priority

NCT03416907
View directory record Official record
Conditions
Consent Forms, Asthma
Interventions
Original consent form, Shortened consent form, Reordered, shortened consent form, Shortened consent form with a highlights box, Interactive, shortened consent form
Behavioral
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Timely Intravenous Magnesium for Asthma in Children

NCT05166811
View directory record Official record
Conditions
Asthma
Interventions
Magnesium Sulfate, Heptahydrate, 0.9% saline
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Years to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Phase 4 Interventional Results available

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

NCT00181207
View directory record Official record
Conditions
COPD, Chronic Bronchitis, Emphysema
Interventions
pneumatic vest, placebo pneumatic vest
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 29, 2026, 5:13 PM EDT
Terminated Phase 1 Interventional

Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression

NCT00444236
View directory record Official record
Conditions
Exercise Triggered Asthma, Gastroesophageal Reflux
Interventions
Nexium, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 29, 2026, 5:13 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867
View directory record Official record
Conditions
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
Interventions
NIR178, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 29, 2026, 5:13 PM EDT
Available No phase listed Expanded access

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

NCT04146571
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive
Interventions
Ensartinib
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
4
States / cities
Stanford, California • Bethesda, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Not applicable Interventional

Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings

NCT03711292
View directory record Official record
Conditions
Antimicrobial Stewardship, Acute Bronchitis, Upper Respiratory Infection
Interventions
Antibiotic Stewardship
Behavioral
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
21 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 29, 2026, 5:13 PM EDT
Terminated Phase 4 Interventional

Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)

NCT00471809
View directory record Official record
Conditions
Asthma
Interventions
Budesonide + Salmeterol + Azithromycin, Budesonide + Salmeterol + Montelukast, Budesonide + Salmeterol + Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
6 Years to 17 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Not applicable Interventional

Electronic Health Record (EHR) Decision Support to Improve Outpatient Asthma Care

NCT00918944
View directory record Official record
Conditions
Asthma
Interventions
Control, Intervention
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2011 · Synced Oct 29, 2026, 5:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

NCT04210492
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
45 Gray (Gy) regimen
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
6
States / cities
Greenwich, Connecticut • Guilford, Connecticut • Hamden, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics

NCT00634036
View directory record Official record
Conditions
Asthma
Interventions
pioglitazone, placebo
Drug
Lead sponsor
Fernando Holguin
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 29, 2026, 5:13 PM EDT
Withdrawn Phase 2 Interventional

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

NCT07428044
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain (Phase 2)

NCT02986334
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Omeprazole, Placebo
Drug
Lead sponsor
Apkar Apkarian
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

NCT01641692
View directory record Official record
Conditions
Asthma
Interventions
GSK573719 Active treatment or Placebo, GSK573719 (Sub-group cohort), Salbutamol/Albuterol
Drug · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Newport Beach, California • Sunset, Louisiana • Bethesda, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 29, 2026, 5:13 PM EDT
Recruiting No phase listed Observational

AeviceMD for Detection of Wheeze in Pediatric and Adult Populations

NCT06691971
View directory record Official record
Conditions
Subject Presenting Wheeze, Asthma, Bronchial Disease, Respiratory Tract Diseases, Pediatric Asthma, Chronic Respiratory Disease
Interventions
AeviceMD
Device
Lead sponsor
Aevice Health Pte. Ltd.
Other
Eligibility
3 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 29, 2026, 5:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Quality of Life Among Families With a Member Who is a Cancer Patient

NCT00544336
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Solid Tumor
Interventions
questionnaire administration, survey administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Phase 2 Interventional

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00777309
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
ARQ 197, Erlotinib, Placebo
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
18
States / cities
Burbank, California • Santa Monica, California • Torrington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 29, 2026, 5:13 PM EDT
Completed No phase listed Observational

Analysis of Inflammation and Microbiome in Patients With Sinusitis and Asthma

NCT02548598
View directory record Official record
Conditions
Asthma, Chronic Rhinosinusitis
Interventions
Endoscopic sinus surgery
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 29, 2026, 5:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegiate Athletic Association (NCAA) Division I Athletes

NCT00752167
View directory record Official record
Conditions
Exercise Induced Bronchospasm, Asthma
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 29, 2026, 5:13 PM EDT
Terminated Phase 1 Interventional Results available

Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01026844
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
erlotinib, hydroxychloroquine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 29, 2026, 5:13 PM EDT
Terminated Phase 1 Interventional

Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery

NCT01159964
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Immunotherapeutic GSK2302032A, different formulations
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Newark, Delaware • Boston, Massachusetts • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 29, 2026, 5:13 PM EDT
Completed Not applicable Interventional

Electronic Monitoring of Medication Adherence in Moderate to Severe Asthma Patients

NCT02913092
View directory record Official record
Conditions
Asthma
Interventions
Electronic sensor and OW education
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 29, 2026, 5:13 PM EDT
Recruiting Phase 4 Interventional

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

NCT06385236
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Dupilumab, Benralizumab
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 29, 2026, 5:13 PM EDT